Tag: approval

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

BEIJING, China, June 25, 2025 (GLOBE NEWSWIRE) -- Zhihu Inc. (NYSE: ZH; HKEX: 2390) (“Zhihu” or the “Company”), a leading online content community in China, today announced that each of the proposed resolutions submitted for shareholders’ approval (the “Proposed Resolutions”) as set forth in the notice of annual general meeting dated May 29, 2025 (the “AGM Notice”) has been adopted at its annual general meeting of shareholders held in Beijing, China today.

MONTREAL, June 25, 2025 (GLOBE NEWSWIRE) -- Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) is proud to announce that it has been named the top company in Corporate Knights’ annual ‘Best 50 Corporate Citizens’ ranking in Canada. This ranking recognizes companies that demonstrate outstanding leadership and commitment to sustainable development. This achievement highlights the importance Boralex places on corporate responsibility, which lies at the core of its business strategy.

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.